Propofol protects human cardiac cells against chemical hypoxia-induced injury by regulating the JNK signaling pathways

LIU HAN\textsuperscript{1,2}, QIANG ZHUO\textsuperscript{3}, YING ZHOU\textsuperscript{1} and YANNING QIAN\textsuperscript{2}

\textsuperscript{1}Department of Anesthesiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006; \textsuperscript{2}Department of Anesthesiology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029; \textsuperscript{3}Department of Pathology, Xuzhou Medical College, Xuzhou, Jiangsu 221004, P.R. China

Received June 7, 2019; Accepted November 7, 2019

DOI: 10.3892/etm.2020.8440

Abstract. Propofol is a widely used intravenous anesthetic shown to exert a cardioprotective role against oxidative stress and ischemia/reperfusion injury in rat cardiac H9c2 cells. However, the regulatory mechanisms and functions of propofol in human cardiomyocytes remain unknown. The present study chemically induced hypoxia with cobalt chloride (CoCl\textsubscript{2}) to mimic cardiomyocyte ischemic injury in human cardiac AC16 and HCM cells. To investigate its underlying mechanisms, propofol was added to the cells before the chemical hypoxia phase. The present results suggested that, in response to hypoxia, mitochondrial membrane potential was lost, and cardiomyocyte viability and superoxide dismutase levels decreased. However, the present results showed that reactive oxygen species and malondialdehyde levels increased. The present results suggested that these effects were significantly reversed following propofol treatment. Additionally, the present results suggested that the protective effect of propofol against CoCl\textsubscript{2}-induced injury may be inhibited by the activation of the JNK signaling pathways. The present results indicated that propofol pre-treatment inhibited CoCl\textsubscript{2}-induced myocardial injury by preventing mitochondrial dysfunction, which may be partially due to the activation of the JNK signaling pathways. Therefore, propofol may exert anti-oxidative effects in human cardiac cells. The present results suggested that propofol may be used as a treatment for oxidative stress-related cardiac disorders.

Introduction

Perioperative acute hypoxic-ischemic cardiac toxicity of anesthetics is one of the most serious complications during surgical procedures, and occurs following the blockade of sodium channels and negative inotropic effect (1-4). To avoid cardiac toxicity, selection of a suitable drug for the maintenance of anesthesia, especially during cardiac surgery, is crucial (5,6). A combination of epidural and general anesthetics have been commonly applied to reduce the use of general anesthetics, such as combining ropivacaine, a local anesthetic, and propofol, a general anesthetic (7,8). Ropivacaine reportedly possesses lower cardiovascular and central nervous toxicity in vivo, in comparison with bupivacaine (9,10). However, its underlying mechanisms remain unknown, and it is unclear whether the mechanism of action is involved in the induction of perioperative ischemic and hypoxic toxicity (11,12).

In contrast, due to its phenolic structure, propofol can prevent ischemic/reperfusion injury (13,14). Furthermore, propofol has an anti-oxidative effect in rat cardiomyocytes and macrophages, which is associated with the suppression of oxidative stress-related enzymes including inducible nitric oxide synthase, superoxide dismutase (SOD) and neutrophil cytosolic factor 1. In addition, propofol is associated with an increase in intracellular nitric oxide release (15,16) and the preservation of Bcl2 expression levels (17). Propofol was shown to protect microglia from hypoxia-induced inflammation and apoptosis by maintaining intracellular Ca\textsuperscript{2+} homeostasis and the activation of the JNK1/Stat3 signaling pathway (18). Furthermore, propofol exerts antiproliferative and anti-invasive effects on hepatocellular carcinoma and rheumatoid arthritis fibroblast-like synoviocytes via the Wnt/\beta catenin (19) and NF-\kappa B signaling pathways (20). Previous studies demonstrated that propofol plays a variety of roles in different cell types via various signaling pathways. However, the effects of propofol, especially when combined with ropivacaine, on human cardiomyocytes is not fully understood.

Therefore, the present study used human AC16 and HCM cardiomyocytes treated with cobalt chloride (CoCl\textsubscript{2}) as an \textit{in vitro} model of cardiomyocyte ischemia. The present study investigated the signaling pathways associated with propofol and/or ropivacaine activity against oxidative stress injury in cardiomyocytes.
Materials and methods

Cell culture. Human adult AC16 and HCM cardiomyocytes (21) (cat. nos. BNCC337712 and BNCC337719; Suzhou BeNa Culture Collection Biotechnology Co., Ltd.) were cultured in DMEM/F12 (Thermo Fisher Scientific, Inc.) supplemented with penicillin 100 U/ml, streptomycin 0.1 mg/ml (Invitrogen; Thermo Fisher Scientific, Inc.) and 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C in a 5% CO₂ incubator. To establish hypoxic conditions, the cardiomyocytes were synchronized, incubated in the complete DMEM/F12 with 500 µmol/l CoCl₂ (Sigma-Aldrich; Merck KGaA; CAS Number 7791-13-1), propofol and/or ropivacaine at different concentrations for 12 h at 37˚C in a 5% CO₂ incubator.

Cell viability assay. To select the appropriate propofol and ropivacaine concentrations, cell viability was assessed using the Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology) according to the manufacturer's instructions. Cardiomyocytes were seeded at a density of 3x10⁴ cells in 96-well plates in sextuplicate and incubated overnight in the complete DMEM/F12 with or without 500 µmol/l CoCl₂ in an atmosphere with 5% CO₂ at 37˚C. After removing the culture medium, cells were treated with propofol (100, 50, 25, 12.5, 6.25 and 0 µg/ml) or ropivacaine at different concentrations (300, 150, 75, 37.5, 18.75 and 0 µg/ml) in the absence of CoCl2 treatment experiments; 100, 50, 25, 12.5 and 0 µg/ml in the 500 µmol/l CoCl2-pretreatment experiments) in fresh medium, repeated eight times, for 48 h at 37˚C. In addition, to determine the synergistic interactions between propofol and ropivacaine, AC16 and HCM cells were treated by 25 µg/ml of propofol and different ropivacaine concentrations (200, 100, 50, 25, 12.5 and 0 µg/ml) for 48 h at 37˚C. The supernatants were discarded and the CCK-8 solution, (dilution, 1:10) was added to each well in complete DMEM/F12, and the cells were incubated for 2 h at 37˚C. Absorbance at 450 nm was measured using a microplate reader (cat. no. MQX200; BioTek Instruments, Inc.). All experiments were repeated four times.

Flow cytometry analysis. Cell apoptosis and mitochondrial membrane potential (ΔΨm) were evaluated using flow cytometry analysis. Cardiomyocytes were incubated in complete DMEM/F12 with or without 50 µg/ml propofol combined with 50 µM Juglanin (cat. no. 5041-67-8; HPLC ≥98%; Shanghai Zeyue Biological Technology Co., Ltd.) for 2 h at 37˚C, and treated with 500 µM CoCl₂ in fresh medium for 12 h at room temperature. Following drug treatments, cells were harvested, washed twice with PBS and stained with Annexin V-FITC/PI Apoptosis Detection kit (cat. no. A211-01; Vazyme Biotech Co., Ltd.) in the binding buffer for 15 min in the dark at 25˚C according to the manufacturer's protocol. The fluorescence intensity of Annexin V/PI-stained cells was analyzed using FACSCanto II flow cytometry (Becton, Dickinson and Company) within 1 h. Early apoptotic Annexin V⁺/PI- cells were counted using FlowJo software version 7.6.1 (Tree Star, Inc.) and the quadrat percentage was considered to indicate the apoptotic ratio.

To determine the ΔΨm, the remaining harvested cells were incubated with JC-1 staining for 20 min at 37˚C according to the manufacturer's protocol of a JC-1 staining kit (cat. no. KGA601; Nanjing Keygene Nanjing Kaiji Biotechnology Co., Ltd.) After washing the samples twice with the incubation buffer in this kit, cells were analyzed using the FACSCanto II flow cytometry (Becton, Dickinson and Company). These experiments were repeated three times.

Reactive oxygen species (ROS) measurements. The effects of propofol on ROS production in CoCl₂-treated AC16 and HCM cells were determined using a ROS-sensitive fluorescent probe (DCFH-DA) (cat. no. D6883; Sigma-Aldrich; Merck KGaA). Then, cells were analyzed using the FACSCanto II flow cytometry (Becton, Dickinson and Company). The cells were seeded at a density of 2x10⁵ cells/well into 6-well plates in triplicate in the following groups: i) Control group, with the cells cultured in complete DMEM/F12; ii) chemical hypoxia group, with the cells cultured in complete DMEM/F12 with 500 µmol/l CoCl₂ for 12 h; and iii) propofol + chemically-induced hypoxia group, with the cells pretreated with 50 µg/ml propofol for 2 h and then exposed to chemically-induced hypoxia. After removing the culture medium, cells were washed with PBS and incubated in 10 µM DCFH-DA in fresh serum-free medium for 30–40 min in a humidified incubator at 37˚C with 5% CO₂ in the dark. Labeled cells were analyzed using FlowJo software version 7.6.1 (Tree Star, Inc.). All assays were performed in duplicate.

SOD and malondialdehyde (MDA) detection. Total intracellular expression levels of MDA and SOD in AC16 and HCM cells were detected using commercially available kits. Cells were divided into three groups, seeded at 1x10⁴ cells/well and the following groups were analyzed: i) Control group, chemically induced hypoxia group; and ii) propofol + chemically induced hypoxia group. To detect MDA and SOD, the supernatants were removed and cells were lysed in 1 ml of cold cell lysis buffer, and then cells were crushed for 30 sec after 5 min. The lysis and further processing were repeated four times. Lysed supernatants were collected by centrifugation at 12,000 x g for 5 min at 4˚C. Then, 0.25 ml of each supernatant, 1.5 ml reagent C solution and 0.3 ml reagent D were mixed (Micro-MDA Assay Reagent kit; cat. no. KG003; Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer's protocol, boiled at 95˚C for 40 min and then cooled in ice water for 10 min. After centrifugation at 3,000 x g for 15 min at 4˚C, absorbance values were detected at 532 nm using a microplate reader. Cell lysis samples were mixed with the reagents of the Superoxide dismutase (SOD) assay kit (cat. no. KGT00150; Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer's instructions. Then, samples were incubated at room temperature for 10 min and the absorbance was detected at 550 nm using a microplate reader. The relative activity levels of SOD (U/ml) were calculated using the formula recommended by the supplier of the kit, and expressed according to absorbance levels. MDA and SOD concentrations were determined based on the constructed standard curve and are expressed as nmol/(mg total protein). All assays were performed in duplicate.

Western blot analysis. Western blotting was used to evaluate the activation of the signaling pathways. Total proteins were extracted from cells that underwent different treatments using ice-cold RIPA lysis buffer (Beyotime Institute of Biotechnology) with a protease inhibitor cocktail (Roche Applied Science), and total protein concentration in every sample was determined using a BCA Protein Assay kit (Beyotime Institute of Biotechnology). Then, 40 µg of total protein solution for each sample was separated by
12% SDS-PAGE and transferred onto PVDF membrane (Bio-Rad Laboratories, Inc.). The membranes were incubated with primary antibodies against JNK1 (1:1,000; cat. no. sc-137018; Santa Cruz Biotechnology, Inc.), phosphorylated (p-)JNK (1:1,000; cat. no. sc-6254; Santa Cruz Biotechnology, Inc.), p38 (1:1,000; cat. no. 8690; Cell Signaling Technology, Inc.), p-p38 (1:1,000; cat. no. 4511; Cell Signaling Technology, Inc.) and GAPDH (1:2,000; cat. no. 5174; Cell Signaling Technology, Inc.) at 4˚C overnight. Then, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody (goat anti-mouse IgG (H+L)-horseradish peroxidase (HRP) conjugate; 1:5,000; A16072SAMPLE; Thermo Fisher Scientific, Inc.; Goat anti-Rabbit IgG (H+L) Secondary Antibody-HRP; 1:5,000; Thermo Fisher Scientific, Inc.) at room temperature for 1 h. Protein bands were detected using the enhanced chemiluminescent (ECL) western blotting detection kit (cat. no. E411-03, Vazyme Biotech Co., Ltd.) and the intensity of each western blot band was quantified using Quantity One 1-D Analysis software v4.5 (Bio-Rad Laboratories, Inc.). All experiments were performed in triplicate.

**Statistical analysis.** Data are presented as mean ± SD and were analyzed using one-way ANOVA followed by Tukey's test. All statistical analyses were performed using GraphPad Prism 4.00 (GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Propofol increases cardiomyocyte viability and inhibits CoCl2-induced cytotoxicity.** CCK-8 assay results suggested that cell viability significantly decreased following a 12-h incubation with increasing concentrations of CoCl2 (0, 125, 250, 500 or 1,000 µm; Fig. 1A) and incubation with 500 µm CoCl2 for different periods (0, 6, 12, 24 and 48 h; Fig. 1B). AC16 and HCM cell viability in the chemically induced hypoxia group was shown to decrease to 62.30% (0.7419/1.1909) and 57.13% (0.7739/1.3546), respectively, compared with the control groups following treatment with 500 µm CoCl2 for 12 h (P<0.01). Therefore, these conditions were selected for further experiments.

To determine the effects of propofol and ropivacaine pretreatment on cardiomyocyte viability, the viability of AC16 and HCM cells treated with propofol or ropivacaine at different concentrations was determined using the CCK-8 assay. The present results suggested that propofol significantly increased cell viability under normal culture conditions in a dose-dependent manner (Fig. 1C). The present results indicated that propofol could reverse the decreased viability of AC16 and HCM cells in a dose-dependent manner when combined with CoCl2 treatment. Moreover, the protective effects of propofol against CoCl2 hypoxia-induced injury were identified to be the highest at 50 µg/ml propofol (Fig. 1D; P<0.01). Compared with the viability observed following the application of propofol, combined propofol and ropivacaine treatment did not increase the viability of cells (Figs. S1 and S2). In addition, regardless of whether the conditions were normoxic or hypoxic, ropivacaine did not affect the viability of AC16 and HCM cells (Fig. S3). Therefore, propofol was selected for further investigation.

**Propofol inhibits activation of the JNK signaling pathways in AC16 and HCM cells exposed to CoCl2.** In order to identify the signaling pathways involved in the anti-apoptotic functions of propofol, the present study investigated the activation of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways. These pathways are reported to be the key signal transduction pathways involved in CoCl2-induced apoptosis in BV2 and HK2 cells (18). However, in the present study, propofol did not affect the phosphorylation of p65 subunit, P38, ERKs and JNK in either AC16 or HCM cells (Fig. S4). The present study also investigated the signaling pathways that may underlie the identified propofol effects. AC16 and HCM cells were pre-incubated...
CoCl₂ was identified to promote the phosphorylation of JNK and P38 in AC16 cells, and the phosphorylation of JNK in HCM cells following 2 h treatment, but these effects were significantly inhibited by propofol treatment (Fig. 2). CoCl₂ did not increase the phosphorylation of P38 in HCM cells, which may be caused by heterogeneity between cell types. The present results indicated that JNK and p38, but not ERK signaling, represented the main components of the apoptotic pathways contributing to CoCl₂-induced apoptosis of AC16 or HCM cells.

**Propofol protects against CoCl₂-induced cardiac cell apoptosis.** CoCl₂ has been reported to induce apoptosis of rat cardiac H9C2 cells (22). Therefore, the present study used Annexin V/PI staining to investigate the apoptotic ratio of AC16 and HCM cells following different treatments (Fig. 3A).
The ratio of cells in the 500 µm CoCl₂-induced hypoxia group was higher compared with the control group (P<0.01). This ratio was significantly reduced after 2 h pretreatment with 50 µg/ml propofol prior to the induction of hypoxia. However, the JNK activator juglanin could counteract this reduction and considerably suppressed the anti-apoptotic effects of propofol pretreatment in CoCl₂-induced cardiac cells (Fig. 3B).

A hypoxia-induced injury may result in reduced mitochondrial membrane potential (23). Therefore, the present study investigated the effects of propofol on ΔΨm using JC-1 staining. The present results suggested 50 µg/ml propofol significantly inhibited CoCl₂-induced decreases in the ΔΨm of AC16 and HCM cells (Fig. 3C and D). Additionally, the present results suggested that juglanin significantly counteracted the recovery effect on ΔΨm induced by pretreatment with propofol and promoted the reduction of ΔΨm induced by CoCl₂ (P<0.05).

Propofol reduces CoCl₂-induced oxidative stress in AC16 and HCM cells. Mitochondria are considered the main source of ROS in cells (24). Therefore, the present study investigated the mechanism underlying the propofol-induced mitochondrial protection from oxidative stress. The production of ROS was significantly increased in the CoCl₂ group compared with the control group (P<0.01), and this was shown to be significantly decreased following propofol pretreatment (Fig. 4A and B). Intracellular MDA and supernatant SOD expression levels were also investigated. The present results suggested that the production of MDA was significantly increased in the CoCl₂ group compared with the control group (P<0.01), whereas the SOD levels significantly decreased compared with the controls (P<0.01; Fig. 4C and D). These effects of CoCl₂ significantly decreased following the application of 25 and 50 µg/ml propofol for 2 h prior to CoCl₂ treatment (P<0.05).
Discussion

Due to its rapid onset of action and rapid recovery profile, propofol is widely used for the initiation and maintenance of general anesthesia, sedation of mechanically ventilated adults, procedural sedation and other similar purposes (25). However, side effects are inevitable and include irregular heart rate, low blood pressure, burning sensation at the site of injection and suppression of breathing (26). Combined application of epidural anesthesia, such as ropivacaine and lidocaine, may reduce the propofol doses required for the induction and maintenance of anesthesia, and further reduce its side effects in clinical practice (27,28). The present study investigated the effects of propofol and/or ropivacaine on cardiomyocytes in vitro under normoxic or CoCl₂-induced hypoxic conditions.

In view of the higher detection sensitivity than other tetrazolium salts such as an MTT assay, CCK-8 is widely used for determination of cell viability in cell proliferation and cytotoxicity assays (29). In the present study, although absorbance values were different in control groups of different cells, which may have resulted from different incubation times, cell viability in all assays was accurately assessed by CCK-8.

CoCl₂ has been used for mimicking pathophysiological hypoxia/ischemic conditions in vitro, including ROS production, by activating the hypoxic signaling pathway (23,30). The present results suggested that CoCl₂ decreased the viability of AC16 and HCM cells in a dose and timedependent manner. To mimic a moderate hypoxic environment, 500 µm CoCl₂ treatment for 12 h was selected for further experiments. The present results suggested that this treatment induced cell apoptosis and ROS and MDA production, decreased SOD production and disrupted the integrity of the mitochondrial membrane leading to a reduction of ΔΨm. The present results suggested that CoCl₂ treatment may induce the continuous flux of superoxide anions and hydrogen peroxide, inducing oxidative stress in the cells, thus reducing the activity of SOD. Therefore, CoCl₂-induced cytotoxicity was suggested to be ROS-dependent.

Propofol was previously reported to protect cells against oxidative stress induced by hydrogen peroxide (31,32), oxygen glucose deprivation (33) and endotoxemia (34), and to inhibit lipid peroxidation in various experimental cell models (35). The present results suggested that propofol significantly increased cell viability under normal culture conditions in a concentration-dependent manner, and the protective effects of propofol pretreatment against CoCl₂ hypoxiainduced injury were greatest at a concentration of 50 µg/ml. The present results indicated that propofol pretreatment decreased cell apoptosis, prevented impairment of mitochondrial membrane integrity, attenuated the release of ROS and MDA and reversed the CoCl₂-induced SOD decrease. The present results suggested that propofol may exert a strong protective effect against oxidative stress-induced injury in cardiomyocytes.

The effects of propofol differ in various cell types due to the activation or inhibition of different signaling pathways (36). However, since ROS-dependent intrinsic apoptosis is generally mediated by MAPK (37), the present study examined the activation of the NF-κB and MAPK/p38/ERK/JNK signaling pathways, which have been reported to be crucial for CoCl₂-induced apoptosis of BV2 (18) and HK2 cells (38).

Following activation of the MAPK signaling cascade ERK plays an anti-apoptotic role, while JNK and p38 exert pro-apoptotic effects during apoptosis. Moreover, the activation of the JNK and p38 signaling pathways was significantly inhibited following exposure to propofol. However, propofol was not shown to affect the phosphorylation of p65, p38, ERK and JNK in AC16 and HCM cells. The effect of CoCl₂ and propofol treatment was similar between the two cell lines but the magnitude was different, which may be caused by cellular heterogeneity. Therefore, further mechanistic studies are required to fully elucidate the effects of propofol on human cardiomyocytes in order to improve the efficacy and decrease the side effects of the application of this anesthetic during cardiac surgeries.

In conclusion, the present results suggested that pretreatment with propofol may protect human cardiac cells from chemical hypoxia-induced injury via the regulation of the JNK signaling pathways. The present results indicated that propofol may be a promising cardioprotective against a variety of oxidative stress injuries in the heart and may be a suitable drug for the maintenance of anesthesia, especially during cardiac surgery. However, it is not fully understood whether other pathways are involved in these effects; therefore, larger cohort studies are required.

Acknowledgements

Not applicable.

Funding

The present study was supported by Nanjing Science and Technology Commission (grant no. 20150325).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LH participated in the design of experiments, carried out the molecular analysis of cells, interpretation and analysis of data, and helped to draft the manuscript. QZ and YZ were involved in drafting the manuscript and participated in all experiments. YQ has been involved in all aspects of the study, including experimental design, analysis and interpretation of data and writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent to participate

Not applicable.

Competing interest

The authors declare that they have no competing interests.
References


16. Xiang Y and Li YH: Comparison of 1.5% lidocaine and 0.5% ropivacaine epidural anesthesia combined with propofol-general anesthesia guided by bispectral index. J Zhejiang Univ Sci B 8: 428-434, 2007.


31. Xiang Y and Li YH: Comparison of 1.5% lidocaine and 0.5% ropivacaine epidural anesthesia combined with propofol-general anesthesia guided by bispectral index. J Zhejiang Univ Sci B 8: 428-434, 2007.


